Browse by author
Lookup NU author(s): Professor Quentin AnsteeORCiD,
Dr Timothy Hardy
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. NAFLD is one of the most important causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming decades, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NAFLD vary worldwide, usually parallel to the prevalence of obesity, but a substantial proportion of patients are lean. The large number of patients with NAFLD with potential for progressive liver disease creates challenges for screening, as the diagnosis of NASH necessitates invasive liver biopsy. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their need for management. While awaiting the development effective therapies, this disease warrants the attention of primary care physicians, specialists and health policy makers.
Author(s): Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E
Publication type: Review
Publication status: Published
Journal: Nature Reviews Gastroenterology and Hepatology
Print publication date: 01/01/2018
Online publication date: 20/09/2017
Acceptance date: 02/04/2016
ISSN (print): 1759-5045
ISSN (electronic): 1759-5053
Publisher: Nature Publishing Group